Choosing a nebulizer for cystic fibrosis applications

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 6, 1997, Pages 414-419

  Geller, David E ^a  

^a NEMOURS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

AEROSOL; AGE; AIRWAY OBSTRUCTION; BACTERIAL INFECTION; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; HUMAN; LUNG DISEASE; NEBULIZER; PARTICLE SIZE; REVIEW;

AEROSOLS; AGE FACTORS; AIRWAY OBSTRUCTION; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG DISEASES; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE;

EID: 0031265473     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199711000-00005     Document Type: Article

References (56)

1. Swift DL: Use of mathematical aerosol deposition models in predicting the distribution of inhaled therapeutic aerosols. In Inhalation Aerosols: Physical and Biological Basis for Therapy, vol 94. Edited by Hickey AJ. New York: Marcel Dekker; 1996:51-81. For the aerosol buff, this book is a comprehensive review of aerosol physics, delivery devices, and the behavior of drug formulations when atomized.
2. Rudolph G, Kobrich R, Stahlhofen W: Modeling and algebraic formulation of regional aerosol deposition in man. J Aerosol Sci 1990, 21(suppl 1):S306-S406.
3. Hardy JG, Newman SP, Knoch M: Lung deposition from four nebulizers. Respir Med 1993, B7:461-465.
4. Clay MM, Pavia D, Clarke SW: Effect of aerosol particle size on bronchodilation with nebulized terbutaline in asthmatic subjects. Thorax 1986, 41:364-368.
5. Zanen P, Go TL, Lammers J-WJ: The optimal particle size for β-adrenergic aerosols in mild asthmatics. Int J Pharmacol 1994, 107:211-217.
6. Zanen P, Go LT, Lammers J-WJ: Optimal particle size for β-2 agonist and anticholinergic aerosols in patients with severe airway obstruction. Thorax 1996, 51:977-980.
7. Smaldone GC, Diot P, Groth M, Ilowite J: Aerodynamic diameter and "respirable mass" as a predictor of lung deposition. Am J Respir Crit Care Med 1997, 155:A668.
8. Fiel SB, Fuchs HJ, Johnson C, Gonda I, Clark AR: Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human Dnase I to patients with cystic fibrosis. Chest 1995, 108:153-156.
9. Shah PL, Scott SF, Geddes DM, Conway S, Watson A, Nazir T, Carr SB, Wallis C, Marriot C, Hodson ME: An evaluation of two aerosol delivery systems for rhDNase. Eur Respir J 1997, 10:1261-1266.
10. Geller D, Eigen H, Fiel S, Lamarre A, Konstan M, Johnson C: Aerosolized dornase alfa in cystic fibrosis: smaller particle size may improve outcome in patients with mild obstructive lung disease. Pediatr Pulmonol 1996,13(suppl):283.
11. Zuberbuhler P, Finlay W, Stapleton K: Lung deposition estimates from a new nebulizer vs those used in rhDNase trials. Pediatr Pulmonol 1996, 13(suppl):310. Data presented at the North American CF Conference, Orlando, FL, 1996.
12. Mallol J, Rattray S, Walker G, Cook D, Robertson CF: Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol 1996, 21:276-281
13. Newhouse MT: Principles of aerosol therapy. Chest 1982, 82(suppl):39S-41S.
14. Ryan G, Dolovich MB, Obminski G: Standardization of inhalation provocation tests: influence of nebulizer output, particle size and method of inhalation. J Allergy Clin Immunol 1981, 67:156-161.
15. Ilowite JS, Gorvoy JD, Smaldone GC: Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987, 136:1445-1449.
16. Lippmann M, Yeates DB, Albert RE: Deposition, retention, and clearance of inhaled particles. Br J Ind Med 1980, 37:337-362.
17. Martonen T, Katz I, Cress W: Aerosol deposition as a function of airway disease: cystic fibrosis. Pharmacol Res 1995, 12:96-102.
18. Thomas SHL, O'Doherty MJ, Graham A, Page CJ, Blower P, Geddes DM, Nunan TO: Pulmonary deposition of nebulized amiloride in cystic fibrosis: comparison of two nebulizers. Thorax 1991, 46:717-721.
19. Laube B, Jashnani R, Dalby R, Zeitlin P: Effects of inspiratory flow rate and bronchodilator on aerosol deposition in CF. Pediatr Pulmonol 1997, (supp 14):294.
20. Everard ML: Aerosol delivery in infants and young children. J Aerosol Med 1996, 9:71-77. Summarizes the challenges we face for aerosol drug delivery in this important age group.
21. Murakami G, Igarashi T, Adachi Y, Sawai M, Yoshizumi A, Okada T: Measurement of bronchial hyperreactivity in infants and preschool children using a new method. Ann Allergy 1990, 64:383-387.
22. Tal A, Golan H, Grauer N, Aviram M, Albin D, Quastel MR: Deposition pattern of radiolabeled salbutamol Inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J Pediatr 1996, 128:479-484.
23. Everard ML, Clark AR, Milner AD: Drug delivery from jet nebulizers. Arch Dis Child 1992, 67:586-591.
24. Chua HL, Collis GG, Newbury AM, Chan K, Bower G, Sly P, LeSouef PN: The influence of age on aerosol deposition in children with cystic fibrosis. Eur Resp J 1994, 7:2185-2191.
25. Salmon B, Wilson NM, Silverman M: How much aerosol reaches the lungs of wheezy infants and toddlers? Arch Dis Child 1990, 65:401-403.
26. Fok TF, Monkman S, Dolovich M, Gray S, Coates G, Paes B, Rashid F, Newhouse M, Kirpalani H: Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1996, 21:301-309.
27. Lesouef P: How should aerosolized drug doses be size-corrected for children of different sizes? Israel J Med Sci 1996, 32(suppl):S22-S23.
28. Newnham DM, Lipworth BJ: Nebulizer performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). Thorax 1994, 49:762-770.
29. Knoch M: The mechanics of nebulizers and the physics of aerosols. Israel J Med Sci 1996, 32(suppl):S20-S21.
30. Alvine GF, Rodgers P, Fitzsimmons KM, Ahrens RC: Disposable jet nebulizers: how reliable are they? Chest 1992, 101:316-319.
31. Hollie MC, Malone RA, Skufca RM, Nelson HS: Extreme variability in aerosol output of the DeVilbiss 646 jet nebulizer. Chest 1991, 100:1339-1344.
32. Smye SW, Shaw A, Norwood HM, Littlewood JM: Some factors influencing the efficiency of a jet nebulizer system. Clin Phys Physiol Meas 1990, 11:167-175.
33. Hambleton G, Hung JC, Super M: Nebulizers in cystic fibrosis. J R Soc Med 1996, 89(suppl 27):14-18.
34. Loffert DF, Ikle D, Nelson HS: A comparison of commercial jet nebulizers. Chest 1994, 106:1788-1793.
35. Newman SP, Pellow PGD, Clarke SW: Drop sizes from medical atomizers (nebulizers) for drug solutions with different viscocities and surface tensions. Atom Spray Technol 1987, 3:1-11.
36. Cipolla DC, Clark AR, Chan HK, Gonda I, Shire SL: Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. STP Pharm Sci 1994, 4:50-62.
37. Taylor KMG, Taylor G, Kellaway IW, Stevens J: The stability of liposomes to nebulization. Int J Pharmacol 1990, 58:57-61.
38. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL: Aminoglycoside penetration, Inactivation and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985, 132:761-765.
39. Levy J, Smith AL, Kenny MA, Ramsey B, Schoenknecht FD: Bioactivity of gentimicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis 1983, 148:1069-1076.
40. Smith AL, Ramsey B: Aerosol administration of antibiotics. Respiration 1995, 62(suppl 1):19-24.
41. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HGM, Bakker W: Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995, 8:1594-1604.
42. Weber A, Smith A, Williams-Warren J, Ramsey B, Covert DS: Nebulizer delivery of tobramycin to the lower respiratory tract. Pediatr Pulmonol 1994, 17:331-339.
43. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, Gore EJ, Redding GJ: Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989, 7:265-271.
44. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, et al.: Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993, 328:1740-1746.
45. Touw DJ, Jacobs FAH, Brimicombe RW, Heijerman HGM, Bakker W, Breimer DD: Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Pediatr Pulmonol 1996, 13(suppl):294.
46. Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A: Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 1997, 23:249-260. A comprehensive study of numerous devices and antibiotic solutions, showing the complex relationship of drug properties to device performance.
47. Coates AL, MacNeish CF, Meisner D, Kelemen S, Thibert R, MacDonald J, Vadas E: The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 1997, 111:1206-1212.
48. Hurley PK, Smye SW, Cunliffe H: Assessment of antibiotic aerosol generation using commercial jet nebulizers. J Aerosol Med 1994, 7:217-228.
49. Coates AL, MacNeish CF, Lands LC, Meisner D, Kelman S, Vadas EB: A comparison of vented versus unvented nebulizers for the delivery of tobramycin. Pediatr Pulmonol 1997, (suppl 14):288.
50. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery B, Smith AL, Ramsey BW: A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 1997, 111:955-962.
51. Ramsey BW: TOBI phase III trial results. Paper presented at the 11th Annual North American CF Conference, Nashville, TN; October, 1997.
52. Standaert TA, Ramsey B, Vasiljev-K M, Montgomery B: Evaluation of aerosolized tobramycin delivered by 4 major European nebulizers. Pediatr Pulmonol 1997, (suppl 14):295.
53. Jensen T, Pedersen SS, Game S, Heilman C, Hoiby N, Koch C: Collstin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 1987, 19:831-838.
54. Valerius NH, Koch C, Hoiby N: Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet 1991, 338:725-726.
55. Geller DE, Standaert TA: The aerosolizatlon efficiency of colistin is nebulizer dependent. Pediatr Pulmonol 1997, (suppl 14):294.
56. VanDevanter D, Tolentino E, VanDalfsen J, Lin B, Montgomery B, Standaert T, Gordon T: Comparison of the antimicrobial, nebulization and airway tolerance properties of colistin and polymyxin E. Pediatr Pulmonol 1997, (suppl 14):289.